DrugPatentWatch.com Announces Drug Patent Expirations for December 2009
Drug Patent Expirations for December 2009
| MIGRANAL | Valeant | dihydroergotamine mesylate | 5,169,849 | Dec 8, 2009 | |||||
| PHOTOFRIN | Axcan Scandipharm | porfimer sodium | 5,145,863 | Dec 15, 2009 | |||||
| XENICAL | Hoffmann La Roche | orlistat | 4,598,089*PED | Dec 18, 2009 | |||||
| CEDAX | Sciele Pharma Inc | ceftibuten dihydrate | 4,812,561 | Dec 20, 2009 | |||||
| OXILAN-300 | Guerbet | ioxilan | 4,954,348 | Dec 21, 2009 | |||||
| OXILAN-350 | Guerbet | ioxilan | 4,954,348 | Dec 21, 2009 | |||||
| DEFINITY | Lantheus Medcl | perflutren | 6,146,657 | Dec 22, 2009 | |||||
| ZANTAC 150 | Glaxosmithkline | ranitidine hydrochloride | 5,102,665*PED | Dec 23, 2009 | |||||
| VALTREX | Glaxosmithkline | valacyclovir hydrochloride | 4,957,924*PED | Dec 23, 2009 | |||||
| ZIAGEN | Glaxosmithkline | abacavir sulfate | 5,089,500*PED | Dec 26, 2009 | |||||
| TRIZIVIR | Glaxosmithkline | abacavir sulfate; lamivudine; zidovudine | 5,089,500*PED | Dec 26, 2009 | |||||
| EPZICOM | Smithkline Beecham | abacavir sulfate; lamivudine | 5,089,500*PED | Dec 26, 2009 | |||||
| CORVERT | Pharmacia And Upjohn | ibutilide fumarate | 5,155,268 | Dec 28, 2009 | |||||
|
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch.com database for complete details. |
|||||||||
Disclaimer:
All trademarks and applicant names are the property of their respective owners or licensors. Drug patent expiration data is presented “as is.” Use of this information is at your own risk. No warranty is expressed or implied. There is no warranty that the drug patent expriation information is error free.
ABOUT DrugPatentWatch ( http://www.DrugPatentWatch.com )
DrugPatentWatch provides information on drug patents and their expirations. Datasets include Paragraph IV challenges, patent claim types, annual sales, patent expirations, failure to pay maintenance fees, ex parte and inter partes reexamination, interference, and disclaimers. Complete details are provided for all FDA-approved small molecule drugs. Annual sales information is available for top-selling drugs. This value-added information supports the critical business functions of patent agents and attorneys, pharmaceutical companies, wholesalers, healthcare payers, and investors.
